Exagen Inc. (Nasdaq: XGN), a diagnostics company specializing in autoimmune disease testing, has announced that preliminary unaudited financial results for the fourth quarter and full year 2025 align with previously issued guidance. The company will present its complete audited financial statements and provide detailed operational updates on March 10, 2026.
Management will host a conference call following the earnings release to discuss financial performance, business developments, and forward-looking priorities with investors and analysts. The preliminary results indicate the company remains on track with its financial projections, providing investors with early visibility into performance metrics ahead of the formal filing.
Exagen's timely communication of results alignment demonstrates continued execution against financial targets in the competitive autoimmune diagnostics market. The March 10 earnings release and subsequent investor call will offer comprehensive insight into the company's operational efficiency and market positioning as it enters the new fiscal year.